Global and United States Neurodegenerative Diseases Therapeutics Market Report & Forecast 2022-2028

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Market Analysis and Insights: Global and United States Neurodegenerative Diseases Therapeutics Market
This report focuses on global and United States Neurodegenerative Diseases Therapeutics market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Neurodegenerative Diseases Therapeutics market size is estimated to be worth US$  million in 2022 and is forecast to a readjusted size of US$  million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Multiple Sclerosis Therapeutics accounting for % of the Neurodegenerative Diseases Therapeutics global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Child was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

In United States the Neurodegenerative Diseases Therapeutics market size is expected to grow from US$  million in 2021 to US$  million by 2028, at a CAGR of % during the forecast period 2022-2028.

Global Neurodegenerative Diseases Therapeutics Scope and Market Size
Neurodegenerative Diseases Therapeutics market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Diseases Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Neurodegenerative Diseases Therapeutics market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
    Multiple Sclerosis Therapeutics
    Alzheimer's Disease Therapeutics
    Parkinson's Disease Therapeutics
    Parkinson's Disease Therapeutics
    Others

Segment by Application
    Child
    Aldult

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    AB Science SA
    AbbVie Inc.
    Acadia Pharmaceuticals Inc.
    Biogen Inc.
    F. Hoffmann La Roche Ltd.
    H Lundbeck AS
    Mitsubishi Chemical Holdings Corp.
    Novartis AG
    Sanofi
    Teva Pharmaceutical Industries Ltd

 1 Study Coverage
    1.1 Neurodegenerative Diseases Therapeutics Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Neurodegenerative Diseases Therapeutics Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Neurodegenerative Diseases Therapeutics Market Size for the Year 2017-2028
        1.2.2 Global Neurodegenerative Diseases Therapeutics Market Size for the Year 2017-2028
    1.3 Neurodegenerative Diseases Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Neurodegenerative Diseases Therapeutics in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Neurodegenerative Diseases Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Neurodegenerative Diseases Therapeutics Market Dynamics
        1.4.1 Neurodegenerative Diseases Therapeutics Industry Trends
        1.4.2 Neurodegenerative Diseases Therapeutics Market Drivers
        1.4.3 Neurodegenerative Diseases Therapeutics Market Challenges
        1.4.4 Neurodegenerative Diseases Therapeutics Market Restraints
    1.5 Study Objectives
    1.6 Years Considered

 2 Neurodegenerative Diseases Therapeutics by Type
    2.1 Neurodegenerative Diseases Therapeutics Market Segment by Type
        2.1.1 Multiple Sclerosis Therapeutics
        2.1.2 Alzheimer's Disease Therapeutics
        2.1.3 Parkinson's Disease Therapeutics
        2.1.4 Parkinson's Disease Therapeutics
        2.1.5 Others
    2.2 Global Neurodegenerative Diseases Therapeutics Market Size by Type (2017, 2022 & 2028)
    2.3 Global Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2028)
    2.4 United States Neurodegenerative Diseases Therapeutics Market Size by Type (2017, 2022 & 2028)
    2.5 United States Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2028)

 3 Neurodegenerative Diseases Therapeutics by Application
    3.1 Neurodegenerative Diseases Therapeutics Market Segment by Application
        3.1.1 Child
        3.1.2 Aldult
    3.2 Global Neurodegenerative Diseases Therapeutics Market Size by Application (2017, 2022 & 2028)
    3.3 Global Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2028)
    3.4 United States Neurodegenerative Diseases Therapeutics Market Size by Application (2017, 2022 & 2028)
    3.5 United States Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2028)

 4 Global Neurodegenerative Diseases Therapeutics Competitor Landscape by Company
    4.1 Global Neurodegenerative Diseases Therapeutics Market Size by Company
        4.1.1 Top Global Neurodegenerative Diseases Therapeutics Companies Ranked by Revenue (2021)
        4.1.2 Global Neurodegenerative Diseases Therapeutics Revenue by Player (2017-2022)
    4.2 Global Neurodegenerative Diseases Therapeutics Concentration Ratio (CR)
        4.2.1 Neurodegenerative Diseases Therapeutics Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Neurodegenerative Diseases Therapeutics in 2021
        4.2.3 Global Neurodegenerative Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Neurodegenerative Diseases Therapeutics Headquarters, Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Neurodegenerative Diseases Therapeutics Headquarters and Area Served
        4.3.2 Global Neurodegenerative Diseases Therapeutics Companies Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Neurodegenerative Diseases Therapeutics Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Neurodegenerative Diseases Therapeutics Market Size by Company
        4.5.1 Top Neurodegenerative Diseases Therapeutics Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Neurodegenerative Diseases Therapeutics Revenue by Players (2020, 2021 & 2022)

 5 Global Neurodegenerative Diseases Therapeutics Market Size by Region
    5.1 Global Neurodegenerative Diseases Therapeutics Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Neurodegenerative Diseases Therapeutics Market Size by Region (2017-2028)
        5.2.1 Global Neurodegenerative Diseases Therapeutics Market Size by Region: 2017-2022
        5.2.2 Global Neurodegenerative Diseases Therapeutics Market Size by Region (2023-2028)

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Neurodegenerative Diseases Therapeutics Market Size YoY Growth 2017-2028
        6.1.2 North America Neurodegenerative Diseases Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 United States
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 China Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
    6.3 Europe
        6.3.1 Europe Neurodegenerative Diseases Therapeutics Market Size YoY Growth 2017-2028
        6.3.2 Europe Neurodegenerative Diseases Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Neurodegenerative Diseases Therapeutics Market Size YoY Growth 2017-2028
        6.4.2 Latin America Neurodegenerative Diseases Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Neurodegenerative Diseases Therapeutics Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Neurodegenerative Diseases Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 AB Science SA
        7.1.1 AB Science SA Company Details
        7.1.2 AB Science SA Business Overview
        7.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Introduction
        7.1.4 AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        7.1.5 AB Science SA Recent Development
    7.2 AbbVie Inc.
        7.2.1 AbbVie Inc. Company Details
        7.2.2 AbbVie Inc. Business Overview
        7.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Introduction
        7.2.4 AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        7.2.5 AbbVie Inc. Recent Development
    7.3 Acadia Pharmaceuticals Inc.
        7.3.1 Acadia Pharmaceuticals Inc. Company Details
        7.3.2 Acadia Pharmaceuticals Inc. Business Overview
        7.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Introduction
        7.3.4 Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        7.3.5 Acadia Pharmaceuticals Inc. Recent Development
    7.4 Biogen Inc.
        7.4.1 Biogen Inc. Company Details
        7.4.2 Biogen Inc. Business Overview
        7.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Introduction
        7.4.4 Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        7.4.5 Biogen Inc. Recent Development
    7.5 F. Hoffmann La Roche Ltd.
        7.5.1 F. Hoffmann La Roche Ltd. Company Details
        7.5.2 F. Hoffmann La Roche Ltd. Business Overview
        7.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Introduction
        7.5.4 F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        7.5.5 F. Hoffmann La Roche Ltd. Recent Development
    7.6 H Lundbeck AS
        7.6.1 H Lundbeck AS Company Details
        7.6.2 H Lundbeck AS Business Overview
        7.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Introduction
        7.6.4 H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        7.6.5 H Lundbeck AS Recent Development
    7.7 Mitsubishi Chemical Holdings Corp.
        7.7.1 Mitsubishi Chemical Holdings Corp. Company Details
        7.7.2 Mitsubishi Chemical Holdings Corp. Business Overview
        7.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Introduction
        7.7.4 Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        7.7.5 Mitsubishi Chemical Holdings Corp. Recent Development
    7.8 Novartis AG
        7.8.1 Novartis AG Company Details
        7.8.2 Novartis AG Business Overview
        7.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Introduction
        7.8.4 Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        7.8.5 Novartis AG Recent Development
    7.9 Sanofi
        7.9.1 Sanofi Company Details
        7.9.2 Sanofi Business Overview
        7.9.3 Sanofi Neurodegenerative Diseases Therapeutics Introduction
        7.9.4 Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        7.9.5 Sanofi Recent Development
    7.10 Teva Pharmaceutical Industries Ltd
        7.10.1 Teva Pharmaceutical Industries Ltd Company Details
        7.10.2 Teva Pharmaceutical Industries Ltd Business Overview
        7.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Introduction
        7.10.4 Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        7.10.5 Teva Pharmaceutical Industries Ltd Recent Development

 8 Research Findings and Conclusion

 9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer

List of Tables
    Table 1. Neurodegenerative Diseases Therapeutics Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Neurodegenerative Diseases Therapeutics Market Trends
    Table 3. Neurodegenerative Diseases Therapeutics Market Drivers
    Table 4. Neurodegenerative Diseases Therapeutics Market Challenges
    Table 5. Neurodegenerative Diseases Therapeutics Market Restraints
    Table 6. Global Neurodegenerative Diseases Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Neurodegenerative Diseases Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Neurodegenerative Diseases Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Neurodegenerative Diseases Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Neurodegenerative Diseases Therapeutics Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Neurodegenerative Diseases Therapeutics Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Neurodegenerative Diseases Therapeutics Revenue Share by Player, 2017-2022
    Table 13. Global Neurodegenerative Diseases Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Neurodegenerative Diseases Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2021)
    Table 15. Top Players of Neurodegenerative Diseases Therapeutics in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Neurodegenerative Diseases Therapeutics Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Neurodegenerative Diseases Therapeutics Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Neurodegenerative Diseases Therapeutics Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Neurodegenerative Diseases Therapeutics Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Neurodegenerative Diseases Therapeutics Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Neurodegenerative Diseases Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Neurodegenerative Diseases Therapeutics Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Neurodegenerative Diseases Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Neurodegenerative Diseases Therapeutics Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Neurodegenerative Diseases Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Neurodegenerative Diseases Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Neurodegenerative Diseases Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. AB Science SA Company Details
    Table 31. AB Science SA Business Overview
    Table 32. AB Science SA Neurodegenerative Diseases Therapeutics Product
    Table 33. AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 34. AB Science SA Recent Development
    Table 35. AbbVie Inc. Company Details
    Table 36. AbbVie Inc. Business Overview
    Table 37. AbbVie Inc. Neurodegenerative Diseases Therapeutics Product
    Table 38. AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 39. AbbVie Inc. Recent Development
    Table 40. Acadia Pharmaceuticals Inc. Company Details
    Table 41. Acadia Pharmaceuticals Inc. Business Overview
    Table 42. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product
    Table 43. Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 44. Acadia Pharmaceuticals Inc. Recent Development
    Table 45. Biogen Inc. Company Details
    Table 46. Biogen Inc. Business Overview
    Table 47. Biogen Inc. Neurodegenerative Diseases Therapeutics Product
    Table 48. Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 49. Biogen Inc. Recent Development
    Table 50. F. Hoffmann La Roche Ltd. Company Details
    Table 51. F. Hoffmann La Roche Ltd. Business Overview
    Table 52. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product
    Table 53. F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 54. F. Hoffmann La Roche Ltd. Recent Development
    Table 55. H Lundbeck AS Company Details
    Table 56. H Lundbeck AS Business Overview
    Table 57. H Lundbeck AS Neurodegenerative Diseases Therapeutics Product
    Table 58. H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 59. H Lundbeck AS Recent Development
    Table 60. Mitsubishi Chemical Holdings Corp. Company Details
    Table 61. Mitsubishi Chemical Holdings Corp. Business Overview
    Table 62. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product
    Table 63. Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 64. Mitsubishi Chemical Holdings Corp. Recent Development
    Table 65. Novartis AG Company Details
    Table 66. Novartis AG Business Overview
    Table 67. Novartis AG Neurodegenerative Diseases Therapeutics Product
    Table 68. Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 69. Novartis AG Recent Development
    Table 70. Sanofi Company Details
    Table 71. Sanofi Business Overview
    Table 72. Sanofi Neurodegenerative Diseases Therapeutics Product
    Table 73. Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 74. Sanofi Recent Development
    Table 75. Teva Pharmaceutical Industries Ltd Company Details
    Table 76. Teva Pharmaceutical Industries Ltd Business Overview
    Table 77. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product
    Table 78. Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 79. Teva Pharmaceutical Industries Ltd Recent Development
    Table 80. Research Programs/Design for This Report
    Table 81. Key Data Information from Secondary Sources
    Table 82. Key Data Information from Primary Sources
List of Figures
    Figure 1. Neurodegenerative Diseases Therapeutics Product Picture
    Figure 2. Global Neurodegenerative Diseases Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Neurodegenerative Diseases Therapeutics Market Size 2017-2028 (US$ Million)
    Figure 4. United States Neurodegenerative Diseases Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Neurodegenerative Diseases Therapeutics Market Size 2017-2028 (US$ Million)
    Figure 6. United States Neurodegenerative Diseases Therapeutics Market Share in Global 2017-2028
    Figure 7. Neurodegenerative Diseases Therapeutics Report Years Considered
    Figure 8. Product Picture of Multiple Sclerosis Therapeutics
    Figure 9. Product Picture of Alzheimer's Disease Therapeutics
    Figure 10. Product Picture of Parkinson's Disease Therapeutics
    Figure 11. Product Picture of Parkinson's Disease Therapeutics
    Figure 12. Product Picture of Others
    Figure 13. Global Neurodegenerative Diseases Therapeutics Market Share by Type in 2022 & 2028
    Figure 14. Global Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. Global Neurodegenerative Diseases Therapeutics Market Share by Type (2017-2028)
    Figure 16. United States Neurodegenerative Diseases Therapeutics Market Share by Type in 2022 & 2028
    Figure 17. United States Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2028) & (US$ Million)
    Figure 18. United States Neurodegenerative Diseases Therapeutics Market Share by Type (2017-2028)
    Figure 19. Product Picture of Child
    Figure 20. Product Picture of Aldult
    Figure 21. Global Neurodegenerative Diseases Therapeutics Market Share by Application in 2022 & 2028
    Figure 22. Global Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2028) & (US$ Million)
    Figure 23. Global Neurodegenerative Diseases Therapeutics Market Share by Application (2017-2028)
    Figure 24. United States Neurodegenerative Diseases Therapeutics Market Share by Application in 2022 & 2028
    Figure 25. United States Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2028) & (US$ Million)
    Figure 26. United States Neurodegenerative Diseases Therapeutics Market Share by Application (2017-2028)
    Figure 27. North America Neurodegenerative Diseases Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 28. United States Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 29. Canada Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. Europe Neurodegenerative Diseases Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 31. Germany Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. France Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. U.K. Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Italy Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Russia Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 37. China Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. Japan Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. South Korea Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. India Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Australia Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. China Taiwan Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Indonesia Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Thailand Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Malaysia Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Latin America Neurodegenerative Diseases Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 47. Mexico Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Brazil Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Argentina Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 51. Turkey Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Saudi Arabia Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. UAE Neurodegenerative Diseases Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. AB Science SA Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 55. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 56. Acadia Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 57. Biogen Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 58. F. Hoffmann La Roche Ltd. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 59. H Lundbeck AS Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 60. Mitsubishi Chemical Holdings Corp. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 61. Novartis AG Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 62. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 63. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed

Market Analysis and Insights: Global and United States Neurodegenerative Diseases Therapeutics Market
This report focuses on global and United States Neurodegenerative Diseases Therapeutics market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Neurodegenerative Diseases Therapeutics market size is estimated to be worth US$  million in 2022 and is forecast to a readjusted size of US$  million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Multiple Sclerosis Therapeutics accounting for % of the Neurodegenerative Diseases Therapeutics global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Child was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

In United States the Neurodegenerative Diseases Therapeutics market size is expected to grow from US$  million in 2021 to US$  million by 2028, at a CAGR of % during the forecast period 2022-2028.

Global Neurodegenerative Diseases Therapeutics Scope and Market Size
Neurodegenerative Diseases Therapeutics market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Diseases Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Neurodegenerative Diseases Therapeutics market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
    Multiple Sclerosis Therapeutics
    Alzheimer's Disease Therapeutics
    Parkinson's Disease Therapeutics
    Parkinson's Disease Therapeutics
    Others

Segment by Application
    Child
    Aldult

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    AB Science SA
    AbbVie Inc.
    Acadia Pharmaceuticals Inc.
    Biogen Inc.
    F. Hoffmann La Roche Ltd.
    H Lundbeck AS
    Mitsubishi Chemical Holdings Corp.
    Novartis AG
    Sanofi
    Teva Pharmaceutical Industries Ltd